Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status

MEK inhibition is potentially valuable in targeting KRAS-mutant non-small cell lung cancer (NSCLC). Here, we analyzed whether concomitant LKB1 mutation alters sensitivity to the MEK inhibitor selumetinib, and whether the metabolism drug phenformin can enhance the therapeutic effect of selumetinib in...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Zhang, Jun, Nannapaneni, Sreenivas, Wang, Dongsheng, Liu, Fakeng, Wang, Xu, Jin, Rui, Liu, Xiuju, Rahman, Mohammad Aminur, Peng, Xianghong, Qian, Guoqing, Chen, Zhuo G., Wong, Kwok-Kin, Khuri, Fadlo R., Zhou, Wei, Shin, Dong M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2017
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5601710/
https://ncbi.nlm.nih.gov/pubmed/28938614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19779
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi